Observational studyCancer immunology, immunotherapy : CII2021

Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study.

Vincenzo Di Noia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.